Rituximab biosimilar (Lonza/Teva Pharmaceutical Industries)

利妥昔单抗生物类似药 (Lonza/Teva Pharmaceutical Industries)

Report date: 2022/07/04 19:38:02

Base Information

Drug NameRituximab biosimilar (Lonza/Teva Pharmaceutical Industries)
Drug Alias Name利妥昔单抗生物仿制药 (Lonza/Teva Pharmaceutical Industries)TL-011
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsArthritis, RheumatoidLymphoma, Large B-Cell, Diffuse
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaUkraine +[12] 
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTeva Pharmaceutical Industries LtdLonza
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTeva Branded Pharmaceutical Products R&D IncTeva Pharmaceutical Industries Ltd
Active IndicationsN/A
Inactive IndicationsArthritis, RheumatoidLymphoma, Large B-Cell, Diffuse

Other Information

ATC CodeL01XC02
Related LinksN/A